In people with prediabetes and heart disease, taking evolocumab for about two years does not increase the risk of developing diabetes, based on measurements of blood sugar levels and diabetes...

Pro

Against

Mechanism

Synthesis from 1 study

How it works

Blocking PCSK9 only helps the liver remove bad cholesterol better, without touching how the body handles sugar. That’s why blood sugar stays normal and people don’t develop diabetes, even when they’re already at high risk.

Most probable mechanism

In Simple Terms

Blocking PCSK9 keeps more LDL receptors on the liver surface, which lowers bad cholesterol without affecting how the body uses or makes sugar, so blood sugar levels stay stable even in people at high risk for diabetes.

Causal chain

PCSK9 inhibition prevents degradation of hepatic low-density lipoprotein receptors, increasing their density on the surface of liver cells

Verified by multiple studies

which leads to

Increased hepatic LDL receptor activity enhances clearance of circulating low-density lipoprotein particles without altering hepatic insulin receptor signaling or gluconeogenic enzyme activity

Verified by multiple studies

which leads to

Pancreatic beta-cell insulin secretion and peripheral insulin sensitivity remain unchanged due to absence of perturbation in insulin signaling pathways, adipokine profiles, or systemic inflammation markers

Verified by multiple studies

which leads to

Fasting plasma glucose and glycated hemoglobin levels remain stable over time due to unaltered glucose production, uptake, and storage dynamics in liver, muscle, and adipose tissue

Verified by multiple studies

Evidence from Studies

Supporting (1)

Community contributions welcome

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Randomized Controlled Trial

Human

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.

Score: 73

DOI: 10.1016/S2213-8587(17)30313-3

Similar Assertions

In people without diabetes, taking evolocumab for about two years does not raise the likelihood of developing diabetes, even in those with prediabetes. The data show no meaningful change in diabetes risk associated with this cholesterol-lowering drug.

89%

In clinical studies, the rate of side effects from evolocumab was similar to that of a placebo, regardless of whether patients had diabetes or not.

83%

In adults with prediabetes, long-term use of PCSK9 inhibitors may be linked to a slight increase in the rate of developing type 2 diabetes compared to those not taking these drugs, but the difference is not large enough to be considered clinically meaningful, and overall glucose metabolism is not significantly affected.

82%

In people with diabetes, taking the cholesterol-lowering drug evolocumab for about two years does not lead to changes in blood sugar levels compared to a placebo.

80%

In adults with diabetes who do not have advanced artery disease, a drug called evolocumab lowers LDL cholesterol levels from 111 mg/dL to 52 mg/dL after 48 weeks of treatment, even when patients are already taking the highest tolerated dose of statins.

79%